22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....
15:30 , Sep 30, 2018 |  BC Extra  |  Preclinical News

Blueprint Medicines unveils preclinical data for rare bone disease program

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sunday. Blueprint...